Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG

(2020) Anthony P. Carnicelli et al.   ANNALS OF INTERNAL MEDICINE

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

(2020) Jan Borén et al.   EUROPEAN HEART JOURNAL

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

(2020) Raul D. Santos et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

(2020) Vera A. Bittner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

(2020) R. Preston Mason et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

(2020) Maciej Banach et al.   JAMA Cardiology

LDL-C: lower is better for longer—even at low risk

(2020) Peter E. Penson et al.   BMC Medicine

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

(2020) Peter E. Penson et al.   Current Atherosclerosis Reports

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

(2020) Matthew J Budoff et al.   EUROPEAN HEART JOURNAL

Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events

(2020) Garima Sharma et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

(2020) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go

(2020) Maciej Banach et al.   JAMA Network Open

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

(2019) Kornelia Kotseva et al.   European Journal of Preventive Cardiology

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

(2019) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mendelian Randomization Study of ACLY and Cardiovascular Disease

(2019) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial

(2019) J. Wouter Jukema et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials

(2019) Federica Fogacci et al.   PHARMACOLOGICAL RESEARCH

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

(2019) Guy De Backer et al.   ATHEROSCLEROSIS

Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort

(2019) Alexander Dressel et al.   VASCULAR PHARMACOLOGY

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion

(2019) Maciej Banach et al.   ATHEROSCLEROSIS SUPPLEMENTS

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

(2019) Nicholas A. Marston et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

(2019) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

(2019) Robert A Hegele et al.   Lancet Diabetes & Endocrinology

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

(2019) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

(2019) Anne C. Goldberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study

(2019) Seth J. Baum et al.   Journal of Clinical Lipidology

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

(2019) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

(2019) Pierre Amarenco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES

(2019) J. Wouter Jukema et al.   CIRCULATION

Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort

(2019) Baris Gencer et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome

(2019) Heinz Drexel et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany

(2018) Winfried März et al.   ATHEROSCLEROSIS

Use of plant sterol and stanol fortified foods in clinical practice

(2018) Montserrat Cofan et al.   CURRENT MEDICINAL CHEMISTRY

The Role of Nutraceuticals in Statin Intolerant Patients

(2018) Maciej Banach et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts

(2018) Ramón Estruch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

(2018) Andrea Poli et al.   PHARMACOLOGICAL RESEARCH

High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry

(2018) Sophie Béliard et al.   ATHEROSCLEROSIS

Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry

(2018) Nina Schmidt et al.   ATHEROSCLEROSIS

Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry

(2018) Michal Vrablik et al.   ATHEROSCLEROSIS

Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study

(2018) Peter Penson et al.   CARDIOVASCULAR RESEARCH

Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience

(2018) Muhammed T. Gürgöze et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels

(2018) Marc S. Sabatine et al.   JAMA Cardiology

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

(2018) Aruna D. Pradhan et al.   AMERICAN HEART JOURNAL

The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk

(2018) Pratik B Sandesara et al.   ENDOCRINE REVIEWS

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial

(2018) Robert Dufour et al.   Journal of Clinical Lipidology

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions

(2018) Peter E. Penson et al.   Journal of Cachexia Sarcopenia and Muscle

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

(2017) Lieven Annemans et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

(2017) Ulf Landmesser et al.   EUROPEAN HEART JOURNAL

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

(2017) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Hypertriglyceridaemia and risk of coronary artery disease

(2017) Željko Reiner   Nature Reviews Cardiology

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

(2017) A. Michael Lincoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

(2017) Arrigo F G Cicero et al.   NUTRITION REVIEWS

Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention

(2017) François Schiele et al.   European Journal of Preventive Cardiology

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

(2017) Marc S Sabatine et al.   Lancet Diabetes & Endocrinology

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

(2017) Marshall B. Elam et al.   JAMA Cardiology

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

(2017) Marc P. Bonaca et al.   CIRCULATION

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease

(2016) Børge G. Nordestgaard   CIRCULATION RESEARCH

The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis

(2016) Jan Borén et al.   CURRENT OPINION IN LIPIDOLOGY

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

(2016) Michael G. Silverman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

(2016) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes

(2015) Baris Gencer et al.   ATHEROSCLEROSIS

Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease

(2015) Bo Kobberø Lauridsen et al.   EUROPEAN HEART JOURNAL

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both

(2015) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins

(2015) Gregory G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus

(2013) Frank M. Sacks et al.   CIRCULATION

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

(2013) et al.   EUROPEAN HEART JOURNAL

Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

(2012) J. C. Mychaleckyj et al.   DIABETES CARE

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses

(2011) H. N. Ginsberg   DIABETES CARE

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes

(2011) Y. Handelsman   DIABETES CARE

Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia

(2011) David J. A. Jenkins et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

(2010)   LANCET

Combination Lipid Therapy in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction

(2008) Zongliang Lu et al.   AMERICAN JOURNAL OF CARDIOLOGY

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

(2008) Michael Miller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY